Key result
Network analysis identifies ATL1101 for cardiac hypertrophy and carvedilol for acute MI.
Why the study?
Research is needed into the exact pathogenesis and effective treatment strategies for cardiac hypertrophy and acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
A computational miRNA-gene-drug network analysis identified novel candidate drug targets for cardiac hypertrophy and acute myocardial infarction.
BACKGROUND: Cardiac hypertrophy and acute myocardial infarction (AMI) are two common heart diseases worldwide. However, research is needed into the exact pathogenesis and effective treatment strategies for these diseases. Recently, microRNAs (miRNAs) have been suggested to regulate the pathological pathways of heart disease, indicating a potential role in novel treatments. RESULTS: In our study, we constructed a miRNA-gene-drug network and analyzed its topological features. We also identified some significantly dysregulated miRNA-gene-drug triplets (MGDTs) in cardiac hypertrophy and AMI using a computational method. Then, we characterized the activity score profile features for MGDTs in cardiac hypertrophy and AMI. The functional analyses suggested that the genes in the network held special functions. We extracted an insulin-like growth factor 1 receptor-related subnetwork in cardiac hypertrophy and a vascular endothelial growth factor A-related subnetwork in AMI. Finally, we considered insulin-like growth factor 1 receptor and vascular endothelial growth factor A as two candidate drug targets by utilizing the cardiac hypertrophy and AMI pathways. CONCLUSION: These results provide novel insights into the mechanisms and treatment of cardiac hypertrophy and AMI.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2018) studied Cardiac hypertrophy and acute myocardial infarction (n=11). Computational drug repurposing network analysis was evaluated on Identification of candidate risk miRNA-gene-drug triplets (MGDTs) and drug repurposing candidates. A computational miRNA-gene-drug network analysis identified ATL1101 as a candidate drug for cardiac hypertrophy via the IGF1R pathway and carvedilol for acute myocardial infarction via the VEGFA pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: